# A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

> **NCT03597581** · PHASE1 · COMPLETED · sponsor: **Inspirna, Inc.** · enrollment: 89 (actual)

## Conditions studied

- Gastrointestinal Cancer
- Gastrointestinal Neoplasms
- Colorectal Cancer
- Colorectal Neoplasms
- Colorectal Carcinoma
- Gastric Cancer
- Gastric Neoplasm
- KRAS Mutation-Related Tumors
- CRC
- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** ompenaclid
- **DRUG:** FOLFIRI
- **DRUG:** Bevacizumab
- **DRUG:** FOLFOX regimen

## Key facts

- **NCT ID:** NCT03597581
- **Lead sponsor:** Inspirna, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-05
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03597581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03597581, "A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03597581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*